there was no rationale reason imo why another pos
Post# of 9122
revenue increased 4.08 x yoy last reported
they are obviously cost conscious and avoiding toxic financing but based on other pennies they could finance for quite some time w toxics IF they wanted to
1 of the reasons i usually avoid biotech is because they usually have horrible financials -not just huge negative R/D retained earnings -but financials that dont support pps- so after seeing pps of other biotechs, when i looked at their financials i would say, u've got to be kidding--because most of them seemed to be de facto bankrupt - i dont see that problem w NNLX
many pennies dont even have a viable product-many never achieve revenue- NNLX has- with revenue growing and costs being cut in an effort to continue avoiding toxics, there is no cause for bk talk imo
they also take forever- thats the name of the game-and sucessful jv's/ partnerships etc properly structured to avoid pitfalls take on average from what i've seen ca 18 months from start of dd- NNLX PR re working w other company was in Oct- but we dont know when they started dd